HUP9802423A2 - Hiperproliferatív megbetegedések kombinált gyógyászati kezelése - Google Patents

Hiperproliferatív megbetegedések kombinált gyógyászati kezelése

Info

Publication number
HUP9802423A2
HUP9802423A2 HU9802423A HUP9802423A HUP9802423A2 HU P9802423 A2 HUP9802423 A2 HU P9802423A2 HU 9802423 A HU9802423 A HU 9802423A HU P9802423 A HUP9802423 A HU P9802423A HU P9802423 A2 HUP9802423 A2 HU P9802423A2
Authority
HU
Hungary
Prior art keywords
hyperproliferative diseases
therapeutical treatment
combined therapeutical
treatment
combined
Prior art date
Application number
HU9802423A
Other languages
English (en)
Inventor
Bruno Tocque
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9802423A2 publication Critical patent/HUP9802423A2/hu
Publication of HUP9802423A3 publication Critical patent/HUP9802423A3/hu
Publication of HU229484B1 publication Critical patent/HU229484B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya egy vagy több, az őnkőgén sejtszignalizációs űtakatlegalább részben gátló nűkleinsav és egy rákellenes terápiás szergyógyhatású kőmbinációja együttes, elkülönített egyidejű vagy egymástkövető alkalmazásra, hiperprőliferatív megbetegedések kezelésére. ŕ
HU9802423A 1995-01-17 1996-01-12 Therapeutical combinations for treatment of hyperproliferative diseases HU229484B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (3)

Publication Number Publication Date
HUP9802423A2 true HUP9802423A2 (hu) 1999-02-01
HUP9802423A3 HUP9802423A3 (en) 2000-11-28
HU229484B1 HU229484B1 (en) 2014-01-28

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802423A HU229484B1 (en) 1995-01-17 1996-01-12 Therapeutical combinations for treatment of hyperproliferative diseases

Country Status (21)

Country Link
US (3) US6262032B1 (hu)
EP (1) EP0800399B1 (hu)
JP (3) JP4580469B2 (hu)
KR (1) KR100385266B1 (hu)
AT (1) ATE222109T1 (hu)
AU (1) AU716364B2 (hu)
BR (1) BR9606969A (hu)
CA (1) CA2209771C (hu)
CZ (1) CZ298710B6 (hu)
DE (1) DE69622989T2 (hu)
DK (1) DK0800399T3 (hu)
ES (1) ES2180729T3 (hu)
FI (1) FI119911B (hu)
FR (1) FR2729295A1 (hu)
HU (1) HU229484B1 (hu)
MX (1) MX9704490A (hu)
NO (1) NO325418B1 (hu)
PT (1) PT800399E (hu)
SI (1) SI0800399T1 (hu)
SK (1) SK283989B6 (hu)
WO (1) WO1996022101A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
AU2002236765A1 (en) * 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2530613A1 (en) * 2003-06-30 2005-01-06 Universite De Lausanne Rasgap derived peptide for selectively killing cancer cells
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751307T2 (de) * 1986-03-28 1995-09-21 Univ Illinois Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna-sequenzen in menschlichen zellen enthalten.
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
DE69329336D1 (de) * 1992-05-28 2000-10-05 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
AU676204B2 (en) * 1992-09-18 1997-03-06 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
FR2729295A1 (fr) 1996-07-19
CZ298710B6 (cs) 2008-01-02
FI973023A0 (fi) 1997-07-16
FI119911B (fi) 2009-05-15
JP2008133291A (ja) 2008-06-12
JP5031921B2 (ja) 2012-09-26
DK0800399T3 (da) 2002-12-02
AU716364B2 (en) 2000-02-24
PT800399E (pt) 2002-12-31
JPH10512559A (ja) 1998-12-02
US20010021395A1 (en) 2001-09-13
EP0800399A1 (fr) 1997-10-15
EP0800399B1 (fr) 2002-08-14
SK95797A3 (en) 1997-12-10
SK283989B6 (sk) 2004-07-07
HUP9802423A3 (en) 2000-11-28
US6262032B1 (en) 2001-07-17
NO973197L (no) 1997-07-09
ATE222109T1 (de) 2002-08-15
ES2180729T3 (es) 2003-02-16
CA2209771C (fr) 2012-01-03
HU229484B1 (en) 2014-01-28
SI0800399T1 (en) 2002-12-31
KR100385266B1 (ko) 2005-09-07
US7884082B2 (en) 2011-02-08
NO973197D0 (no) 1997-07-09
JP2012036201A (ja) 2012-02-23
CZ226297A3 (en) 1997-10-15
FR2729295B1 (hu) 1997-02-28
DE69622989T2 (de) 2002-12-05
CA2209771A1 (fr) 1996-07-25
BR9606969A (pt) 1997-11-04
DE69622989D1 (de) 2002-09-19
US20050209177A9 (en) 2005-09-22
NO325418B1 (no) 2008-04-21
FI973023A (fi) 1997-07-16
WO1996022101A1 (fr) 1996-07-25
US20040127437A1 (en) 2004-07-01
AU4542996A (en) 1996-08-07
KR19980701449A (ko) 1998-05-15
JP4580469B2 (ja) 2010-11-10
MX9704490A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
HUP9802423A2 (hu) Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
NO164656C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 1-(4-amionfenyl)-4-methyl-7,8-methylendioxy-3,4-dihydro-5h-2,3-benzodiazepin.
ES2162110T3 (es) Derivados de la quinolina antimalaria.
NO980296D0 (no) Forbedrede terapeutiske midler
FI964619A0 (fi) Epilepsialääkkeiden iholle annostelu
HUP0002836A2 (hu) Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
AU1278600A (en) Novel therapeutic application of nicergoline
EE9700235A (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NO982562D0 (no) Sammensetning for behandling av smerte
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE29501910U1 (de) Transdermales therapeutisches den Wirkstoff Dimethisoquin enthaltendes System
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
DK0900078T3 (da) Anvendelse af benzonaphthalenderivater til fremstilling af lægemidler til behandling af sygdomme i nervesystemet
IT1304852B1 (it) Miscela di piante medicinali per la prevenzione e la cura delleemorroidi.

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI I, HU